Get the Daily Brief
Latest Biotech News
Novartis and Abogen deepen RNA-platform autoimmune ambitions
Novartis has agreed to buy exclusive worldwide rights to Abogen Biosciences’ lead mRNA-encoded CD19xCD3 T-cell engager, ABO2203, paying $575 million upfront in a deal that could total about $7.8...
In-vivo CRISPR earns FDA clearance for hereditary angioedema
The FDA has approved lonvoguran ziclumeran (lonvo-z), Intellia Therapeutics’ one-time, in vivo mRNA-lipid nanoparticle genome-editing treatment for hereditary angioedema (HAE), after the program...
AnaCardio raises fresh capital for Phase IIb advanced heart failure program
AnaCardio has closed a €62.5 million ($70.5 million) Series B financing to advance its oral calcium-sensitizing contractile agent, AC01, through Phase IIb development for chronic advanced heart...
Immune checkpoint targeting shows mixed efficacy – IDO1 inhibitor plus vaccine disappoints in melanoma
A clinical trial testing an IDO1 inhibitor in combination with a therapeutic melanoma vaccine failed to boost tumor-fighting T cells in advanced melanoma. Researchers led by Craig L. Slingluff at...
Sanofi and Regeneron expand next-generation Dupixent-style immunology pipeline
Sanofi and Regeneron have broadened their long-running antibody alliance by adding four new long-acting immunology programs tied to IL-4/IL-13 biology, in a deal worth up to $8 billion. Sanofi...
Lilly delivers another obesity-cardiometabolic differentiation with amylin–GLP-1/GIP combo
Eli Lilly presented Phase IIb data for a combination of the amylin agonist eloralintide plus tirzepatide (Zepbound) in obese patients with type 2 diabetes, reporting weight loss of 23.3% at the...
Abogen and RNA platform deal confirmation – second reporting thread
A separate report reiterated the key deal terms for the Novartis–Abogen licensing agreement, emphasizing the scope of exclusivity around ABO2203 and the size of the upfront payment. The coverage...
Venture backing for risk-limited heart failure oral therapy
AnaCardio’s Series B announcement continues to reinforce investor interest in differentiated mechanisms for HFrEF, particularly oral delivery strategies aimed at contractility modulation. The...
FDA safety/clinical signal in advanced cancer immunotherapy adverse event tracking
A large case review linked the checkpoint inhibitor nivolumab to rare cytokine storm events, reinforcing that even established immunotherapies can produce severe immune-related toxicities in a...
Policymaker shift: HHS launches programs to speed clinical trials in response to foreign competition
The U.S. Department of Health and Human Services unveiled new initiatives aimed at speeding clinical development, citing increased competition from countries such as China and Australia. The...
Regulatory milestone: in vivo CRISPR for hereditary angioedema
The FDA has approved Intellia Therapeutics’ one-time in vivo CRISPR medicine for hereditary angioedema (HAE), delivering a Phase III-to-BLA regulatory pathway for lonvoguran ziclumeran (lonvo-z)....
Immunology dealmaking: Sanofi and Regeneron expand long-acting antibody pipeline
Sanofi and Regeneron broaden their long-standing immunology alliance with a deal that adds four next-generation long-acting antibody programs tied to IL-4/IL-13 signaling. Sanofi will pay...
Clinical development: Lilly advances amylin–tirzepatide combination data
Eli Lilly presented new Phase IIb results for an amylin agonist combination—eloralintide plus tirzepatide (Zepbound)—showing weight-loss outcomes in obese patients with type 2 diabetes. In the...
AI + drug discovery infrastructure: Talus Bio launches structure-free binding model
Talus Bioscience released Ptarmigan-1, a “structure-free” AI model intended to predict small-molecule binding sites across the human proteome, including proteins that are difficult to model with...
Biotech finance: Kallyope rebrands as TriGemX and secures $94M
Kallyope has rebranded as TriGemX Bio and raised $94 million to advance a migraine pipeline that focuses on a Phase 3 program carried forward after a corporate restructuring. The funding is...
Regulatory/policy: US HHS launches programs to speed clinical trials
HHS unveiled new initiatives aimed at accelerating US clinical trials as competition from China and other regions intensifies. The “Surpass” program is designed to push clinical development toward...
Rare disease/oncology: FDA approval is not the only signal—radioligand and imaging progress
Early translational updates are emerging in oncology imaging and therapy, highlighted by new radioligand development and companion biomarker approaches. A double-target radioligand (INN02)...
Oncology: cryoablation shows promise for oligoprogressive disease
A new study reports that cryoablation could help manage oligoprogressive disease—situations where cancer progression occurs only in a few lesions while broader disease remains controlled. The...
Safety pharmacovigilance: immune checkpoint blockade linked to rare platelet disorder
A new safety analysis links immune checkpoint inhibitors to a rare blood platelet disorder, reported across two global drug safety databases. The work highlights immune checkpoint blockers—drugs...
Venture/startups: Parakeet Health raises $10M for AI patient outreach automation
Parakeet Health raised $10 million to automate patient outreach, using AI to call, text, and email patients to schedule and follow up on appointments and referrals. The startup’s approach targets...